We are presenting a metastatic breast cancer female patient undergoing both immunosuppressive treatment after liver transplantation due to cryptogenic liver failure and anti‐programmed death ligand 1 (PDL1) medication—atezolizumab whose liver enzymes and tacrolimus level we have monitored intensively through 18 months and is still ongoing. This evidence concerns the gene CD274 and Hepatic failure.